TW202315889A - 抗體 - Google Patents

抗體 Download PDF

Info

Publication number
TW202315889A
TW202315889A TW111131251A TW111131251A TW202315889A TW 202315889 A TW202315889 A TW 202315889A TW 111131251 A TW111131251 A TW 111131251A TW 111131251 A TW111131251 A TW 111131251A TW 202315889 A TW202315889 A TW 202315889A
Authority
TW
Taiwan
Prior art keywords
hla
antibody
seq
antibodies
cells
Prior art date
Application number
TW111131251A
Other languages
English (en)
Chinese (zh)
Inventor
卡洛琳 貝爾托
湯瑪士 科力
妮莎 達迪
卡羅布蘭登 德理
大衛 保羅 胡弗瑞斯
安 懷特
蓋勒 樂弗里克
路絲 麥克霍恩
維多利亞 奧多德
克萊爾 湯普森
凱芮 路易斯 泰森
Original Assignee
比利時商Ｕｃｂ生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商Ｕｃｂ生物製藥公司 filed Critical 比利時商Ｕｃｂ生物製藥公司
Publication of TW202315889A publication Critical patent/TW202315889A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111131251A 2021-08-19 2022-08-19 抗體 TW202315889A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2111905.2 2021-08-19
GBGB2111905.2A GB202111905D0 (en) 2021-08-19 2021-08-19 Antibodies

Publications (1)

Publication Number Publication Date
TW202315889A true TW202315889A (zh) 2023-04-16

Family

ID=77913991

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111131251A TW202315889A (zh) 2021-08-19 2022-08-19 抗體

Country Status (16)

Country Link
US (1) US20250026836A1 (https=)
EP (1) EP4388007A1 (https=)
JP (1) JP2024535692A (https=)
KR (1) KR20240046577A (https=)
CN (1) CN118369341A (https=)
AR (1) AR126820A1 (https=)
AU (1) AU2022330347A1 (https=)
BR (1) BR112024001989A2 (https=)
CA (1) CA3227160A1 (https=)
CL (1) CL2024000115A1 (https=)
CO (1) CO2024001711A2 (https=)
GB (1) GB202111905D0 (https=)
IL (1) IL310245A (https=)
MX (1) MX2024002069A (https=)
TW (1) TW202315889A (https=)
WO (1) WO2023021187A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054312A1 (en) * 2023-09-05 2025-03-13 Tizona Therapeutics Hla-g antibodies in antibody-drug conjugates
KR102793781B1 (ko) * 2023-10-12 2025-04-14 주식회사 아이엠바이오로직스 Hla-g에 특이적으로 결합하는 항체 및 이의 용도
GB202319122D0 (en) * 2023-12-14 2024-01-31 Kbio Holdings Ltd Antibody
CN121027507A (zh) * 2025-10-31 2025-11-28 杭州华得森生物技术有限公司 基于多抗体稳定预混液的多重免疫荧光染色试剂盒及其制备方法与应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
PT1049787E (pt) 1998-01-23 2005-04-29 Vlaams Interuniv Inst Biotech Derivados de anticorpos multipropositos
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
WO2013068571A1 (en) 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
AU2017272875B2 (en) * 2016-06-03 2023-10-19 Invectys Anti HLA-G specific antibodies
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
EP3434688A1 (en) * 2017-07-24 2019-01-30 Commissariat à l'Energie Atomique et aux Energies Alternatives Hla-g transcripts and isoforms and their uses
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
NZ774376A (en) 2018-09-27 2025-11-28 Tizona Therapeutics Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies

Also Published As

Publication number Publication date
GB202111905D0 (en) 2021-10-06
KR20240046577A (ko) 2024-04-09
CL2024000115A1 (es) 2024-06-28
AR126820A1 (es) 2023-11-15
CA3227160A1 (en) 2023-02-23
WO2023021187A1 (en) 2023-02-23
JP2024535692A (ja) 2024-10-02
AU2022330347A1 (en) 2024-02-01
CO2024001711A2 (es) 2024-03-07
CN118369341A (zh) 2024-07-19
IL310245A (en) 2024-03-01
BR112024001989A2 (pt) 2024-04-30
MX2024002069A (es) 2024-03-15
US20250026836A1 (en) 2025-01-23
EP4388007A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
US10301388B2 (en) Antibody agents specific for human CD19 and uses thereof
JP7414226B2 (ja) Ｃｄ２２を標的とする構築物及びその使用
US20250026836A1 (en) Anti-hla-g antibodies
EP3299392A1 (en) Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates
CN112513080A (zh) Vista抗原结合分子
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
CN108495864A (zh) 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法
IL302278A (en) Combination treatment
EP4403572A1 (en) Anti-human cd3 antibody and use thereof
CN115461371B (zh) 靶向ox40的抗体及其制备方法和应用
KR20230169944A (ko) Mage-a4 펩티드-mhc 항원 결합 단백질
KR20230166120A (ko) 새로운 tnfr2 결합 분자
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置
JP2023551981A (ja) 多重特異性抗体及び抗体の組み合わせ
JP2025534237A (ja) Ｍａｇｅ－ａ４ペプチドデュアルｔ細胞エンゲージャー
EP4714975A1 (en) Antibody binding lilrb4 and cd3, and use thereof
KR20250150019A (ko) 자가면역질환 치료를 위한 항-cd123 키메라 항원 수용체 t 세포의 용도
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
CN116438198A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
KR20250143344A (ko) 항-cdh6 항체 및 이의 용도
WO2025210181A1 (en) Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
WO2025215160A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide
KR20240046557A (ko) 항-b7-h4 항체 및 이의 제조 방법과 용도